Smith & Nephew is pursuing a massive share repurchasing program and continuing a quest for new acquisitions.
Covance is counting on Asia for an explosion in drug development, and the company has expanded its core lab capacity by 50% in Singapore to serve the growing market for clinical testing in the region.
With a clear eye toward expanding its focus on emerging markets, Smith & Nephew this week announced plans to snatch up its long-time Brazilian-based distributor.
Sanofi CEO Christopher Viehbacher is barnstorming Asia, spreading news of growth along the way. In Vietnam, he announced a new $75 million plant to boost supplies in the region.
Fast-developing countries such as China and India offer the promise of fast growth in drug sales, but it's more difficult to tap those markets--and as Booz & Co. points out in a new report, every country requires its own idiosyncratic strategy.
New manufacturing capacity has come online, and more is in the pipeline, as drugmakers see opportunity to fill vials with injectable drugs and shortages with higher-priced products.
Bayer's new drugs are bringing home the bacon. The German drugmaker raised its 2015 forecast for 5 key products to €2.5 billion ($3.3 billion)--and confirmed previous promises that those drugs would surpass €5.5 billion by 2020.
Medtronic CEO Omar Ishrak has long said he want his company to get 20% of its revenue from emerging markets by 2016, and the device giant made some headway last quarter on the way to $4 billion in total revenue.
Indian stent makers are becoming increasingly viable competitors in international markets, adding another layer to an industry already crowded with a number of players.
For years now Big Pharma's deep pockets have provided the big bucks needed to drive multibillion-dollar deals in biopharma--and quite a few of the smaller ones as well.